PUNE, INDIA, April 13, 2018 /EINPresswire.com/ — WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Pulmonary Embolism – Pipeline Review, H1 2018”
Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytic.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2989072-pulmonary-embolism-pipeline-review-h1-2018
Top Companies mentioned
Accu-Break Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Dong-A Socio Holdings Co Ltd
Hoffmann-La Roche Ltd
Pulmonary Embolism Industry Major Outlook
Pharmaceutical and Healthcare latest pipeline guide Pulmonary Embolism – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pulmonary Embolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II and Preclinical stages are 2, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively
Pulmonary Embolism – Competitive Analysis
Key players are making innovative developments in Pulmonary Embolism industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector
The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Embolism.
The pipeline guide reviews pipeline therapeutics for Pulmonary Embolism by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Pulmonary Embolism therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Pulmonary Embolism therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Embolism.
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2989072-pulmonary-embolism-pipeline-review-h1-2018
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here
Source: EIN Presswire